Oppenheimer assumed coverage of Tarsus Pharmaceuticals (TARS) with an Outperform rating with a price target of $75, up from $72. The firm notes the company reported Q1 2025 topline of $78.3M, beating consensus estimates, with volume of about 72K surpassing guidance. XDEMVY’s momentum remains strong, driven by its growth initiatives. Management highlighted encouraging shifts in prescribing patterns from monthly to weekly prescribing, noting that thousands of target ECPs remain below capacity. Oppenheimer is encouraged by broad commercial, Medicare, and Medicaid coverage. With sales force expansion, coverage, DTC, and evidence generation progressing, plus a strengthened balance sheet, the firm believes XDEMVY’s momentum is well-poised to grow.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Promising Growth Trajectory of Tarsus Pharmaceuticals: Buy Rating Supported by Unique Product Positioning and Strong Market Presence
- Tarsus Pharmaceuticals assumed with a Buy at H.C. Wainwright
- Elanco sells royalty, milestone rights for Xdemvy to Blackstone for $295M
- Tarsus Pharmaceuticals’ Earnings Call Highlights Robust Growth
- Tarsus Pharmaceuticals: Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating